REG - Trellus Health PLC - Directorate Change

Trellus HealthAnnouncement

04/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220104:nRSD2504Xa&default-theme=true

RNS Number : 2504X  Trellus Health PLC  04 January 2022

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Directorate Change

 

LONDON, UK. AND NEW YORK, U.S. (4 January 2022). Trellus Health plc (AIM:
TRLS), which is commercialising a scientifically validated, resilience-based,
connected health solution for chronic condition management, announces that
Niyum Gandhi has informed the Board that due to his commitment to his new role
as Chief Financial Officer and Treasurer at Mass General Brigham (Boston, MA)
he is unable to continue as a Non-Executive Director of the Company, and has
stepped down with immediate effect. The Company will commence a search for a
new Non-Executive Director and a further update will be made as appropriate.

 

Monique Fayad, CEO of Trellus Health, said: "We are deeply grateful for Niyum
Gandhi's contribution and commitment to the Trellus Health Board since the
Company's inception. In his role as Chief Population Health Officer at the
Mount Sinai Health System, Niyum understood the profound need for healthcare
innovations to improve multidisciplinary care access for chronic and
underserved populations. We benefited greatly from his expertise, insights and
industry relationships."

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Monique Fayad, CEO                                       Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is a leading pioneer in resilience-driven care and
the first digital health company focused on the intersection of chronic
physical conditions and mental health. Trellus Health's digital-first chronic
care management solution integrates convenient access to a licensed
multidisciplinary care team with a suite of tools for resilience assessment,
education and behavior modification, remote monitoring, health maintenance and
prevention. Through its TrellusElevate™ connected care platform and
companion App, the company enables coordination and delivery of expert
whole-person care, addressing both clinical and behavioral health together, in
context, to improve outcomes and reduce healthcare costs for patients,
employers, and the healthcare system.

 

Trellus Health is commercialising the provision of digital chronic condition
management solutions for employers and health plans that utilise the
scientifically validated resilience-based methodology and a proprietary
HIPAA-compliant technology platform called TrellusElevate™ to coordinate and
deliver personalised care remotely via telehealth. The Company is initially
focused on Inflammatory bowel disease ("IBD"), which includes the chronic
incurable conditions of Crohn's Disease and ulcerative colitis, but considers
its approach to have potential utility and demand across many chronic
conditions.  A direct-to-consumer (DTC) offering is also being devised for
IBD, allowing patients to pay directly or submit claims for insurance
reimbursement utilising existing procedural codes.

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the proprietary methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. The proprietary methodology and
resilience-driven multidisciplinary care model have been scientifically
validated to demonstrate meaningful improvements in patient outcomes and over
85 per cent. reduction in unplanned healthcare utilisation (emergency
department visits and hospitalisations) which the directors of the Company
believe indicates the potential for significant cost savings for healthcare
payers.

 

The Company was founded by Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer,
PhD, both with decades of combined experience in IBD and
psychogastroenterology, respectively. Trellus Health's patent-pending
GRITT(TM )resilience assessment and personalized treatment methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS.  For more information on Trellus Health,
visit www.trellushealth.com (https://trellushealth.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABCGDBXXGDGDX